Metastatik Meme Kanserli Hastaların Klinik Özellikleri ve Tedavi Sonuçları: Tek Merkez Deneyimi

Amaç: Meme kanseri kadınlarda en sık görülen kanserdir ve bir numaralı kansere bağlı ölümnedenidir. Bu çalışmada merkezimizde takip edilen metastatik meme kanseri (MMK) tanılıhastaların klinik özelliklerini ve tedavi sonuçlarını incelemek amaçlanmıştır.Gereç ve Yöntemler: Çukurova Üniversitesi Tıbbi Onkoloji Bilim Dalı’nda 2011—2017 yıllarındatakip edilen 65 MMK’li hasta çalışmaya dahil edildi. Hastaların klinik ve tedavi verileri retrospektif olarak incelendi.Bulgular: Hastaların çoğunda sadece kemik metastazı vardı. Sonradan metastatik evreye geçen 45 hastanın %66,6’sında yeniden biyopsi yapılmıştı; bu hastaların %20’sinde tümör biyolojisi değişmişti ve değişiklikler istatistiksel olarak anlamlıydı (p=0,0056). Metastatik evredeprogresyonsuz sağkalım 10 ay, ortalama sağkalım 34 ay olarak hesaplandı.Tartışma ve Sonuç: Hastaların sağkalım verileri literatürle uyumluydu. Yeni kullanıma girenajanlar, hedefleyici tedavilerdeki gelişmeler ve tümör biyolojisindeki olası değişimler gözönünde bulundurularak, relapslarda yeniden biyopsi yapılması kritik önemdedir.

Clinical Characteristics and Treatment Outcomes of Patients with Metastatic Breast Cancer: A Singlecenter Experience

Aim: Breast cancer is the most common cancer and the leading cause of cancer-related death among women. In this study, we aimed to investigate the clinical characteristics and treatment outcomes of patients who were diagnosed with metastatic breast cancer (MBC) and followed up at our center. Materials and Methods: The study included a total of 65 patients with MBC who were followed up at the Medical Oncology Department of the Çukurova University during the years 2011 to 2017. Clinical and treatment data of the patients were reviewed retrospectively. Results: Most of the patients had only bone metastases. Re-biopsy was performed in 66.6% of 45 patients who subsequently progressed to metastatic stages; in 20% of these patients there had been statistically significant changes in the tumor biology (p=0.0056). The metastatic-stage progression-free survival was calculated to be 10 months and the overall survival was 34 months. Discussion and Conclusion: The patient survival data were consistent with the literature. Considering the recently introduced agents, developments in targeted treatments, and possible changes in the tumor biology, it is crucial that a re-biopsy be performed in relapses.

PDF

___

1. Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1–32.
2. Güth U, Elfgen C, Montagna G, Schmid SM. Long-term survival and cure in distant metastatic breast cancer. Oncology. 2019;97(2):82–93.
3. Raina V, Bhutani M, Bedi R, Sharma A, Deo SV, Shukla NK, ve ark. Clinical features and prognostic factors of early breast cancer at a major cancer center in North India. Indian J Cancer. 2005;42(1):40–5.
4. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, ve ark. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700–12.
5. Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, ve ark. Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol. 2017;34(7):119.
6. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, ve ark. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–72.
7. Bansal C, Singh US, Misra S, Sharma KL, Tiwari V, Srivastava AN. Comparative evaluation of the modified Scarff–Bloom–Richardson grading system on breast carcinoma aspirates and histopathology. Cytojournal. 2012;9:4.
8. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.
9. Ogiya R, Sagara Y, Niikura N, Freedman RA. Impact of subtype on survival of young patients with stage IV breast cancer. Clin Breast Cancer. 2019;19(3):200–7.
10. Leone BA, Vallejo CT, Romero AO, Machiavelli MR, Pérez JE, Leone J, ve ark. Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. Breast Cancer Res Treat. 2017;161(3):537–48.
11. Sundquist M, Brudin L, Tejler G. Improved survival in metastatic breast cancer 1985–2016. Breast. 2017;31:46– 50.
12. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, ve ark. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018;29(8):1634–57.
13. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, ve ark. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22(16):3302–8.
14. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010;21(11):2169–74.
15. Pal SK, Dehaven M, Nelson RA, Onami S, Hsu J, Waliany S, ve ark. Impact of modern chemotherapy on the survival women presenting with de no metastatic breast cancer. BMC Cancer. 2012;12:435.
16. Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, ve ark. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol. 2016;27(2):256– 62.
17. Chia SK, Speers CH, D’Yachkova Y, Kang A, MalfairTaylor S, Barnett J, ve ark. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2017;110(5):973–9.
18. Ponde N, Brandao M, El-Hachem G, Werbrouck E, Piccart M. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev. 2018;67:10– 20.
19. Le Saux O, Lardy-Cleaud A, Frank S, Debled M, Cottu PH, Pistilli B, ve ark. Assessment of the efficacy of successive endocrine therapies in hormone receptorpositive and HER2-negative metastatic breast cancer: a real-life multicenter national study. Eur J Cancer. 2019;118:131–41.
20. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, ve ark. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–63.
21. Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, ve ark. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2012;38(6):708–14.
22. de Dueñas EM, Hernández AL, Zotano AG, Carrión RM, López-Muñiz JI, Novoa SA, ve ark. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. Breast Cancer Res Treat. 2014;143(3):507–15.